The Hague, March 4. / TASS /. The European Medicines Agency (EMA) has confirmed the safety of vaccines against the Comirnaty coronavirus, jointly developed by Pfizer from the USA and BioNTech from Germany, and Modern by the American company of the same name. This is stated in the monthly reports on the safety of drugs distributed on Thursday, based on data from around the world.
As the document notes for both vaccines, "the benefits in terms of preventing coronavirus infection continue to outweigh any risks, so there are no recommended changes regarding their use."
The agency paid particular attention to the possible impact of side effects on deaths after vaccination. "In most cases, the development of (many) existing diseases appears to be a plausible explanation for death," the reports said. "Palliative care was provided for some patients prior to vaccination. An assessment of the available data indicates that there is no safety concern [of the drugs]."
For both vaccines, it is recommended that you continue to monitor for severe allergic reactions. For Comirnaty, two new side effects have been identified - diarrhea and nausea.
The EMA issued an interim marketing authorization for the Comirnaty vaccine on December 21 last year. This was followed by the approval of Moderna on January 6 in the EU.
Also at the EU level, a vaccine developed by the British-Swedish company Astrazenec and the University of Oxford has been approved. Earlier Thursday, it was announced that the EMA had begun a gradual examination of the Russian Sputnik V coronavirus vaccine.